Fate Therapeutics Inc (FATE) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $8. ROTH Capital advised their investors in a research report released on Sep 22, 2016.
Many Wall Street Analysts have commented on Fate Therapeutics Inc. H.C. Wainwright Resumed Fate Therapeutics Inc on Jul 28, 2016 to “Buy”, Price Target of the shares are set at $9.
Fate Therapeutics Inc opened for trading at $3.03 and hit $3.23 on the upside on Tuesday, eventually ending the session at $3.19, with a gain of 6.33% or 0.19 points. The heightened volatility saw the trading volume jump to 2,78,026 shares. Company has a market cap of $92 M.
Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.